Avextra Supports First Fully EU-Funded Psilocybin Therapy Study, Now Approved by EMA
12. Dezember 2024 07:00 ET
|
Avextra Pharma GmbH
Exclusive Industry Role: Avextra is the industry partner in the first EU-funded project focused on psychedelic-assisted therapy for patients in palliative care suffering from depression, with a total...
Avextra Portugal Unveils Advanced Breeding Program to Develop Proprietary THC and CBD Cultivars, Establishing a Key IP Pillar
20. November 2024 07:00 ET
|
Avextra AG
Avextra Portugal launches an innovative in-house breeding program to develop proprietary cannabis varieties with specific, consistent and reproducible cannabinoid and terpene profiles.Over a two-year...
Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial Using a Proprietary Cannabis-based Medicine for the Treatment of the Symptoms of Neurodegenerative Diseases
08. Oktober 2024 07:00 ET
|
Avextra AG
The Italian Medicines Agency AIFA and the Italian Ministry of Health have granted formal approval for NEUROBIS; a multi-centre Phase II study to evaluate safety, and efficacy of an Avextra oral...
Avextra und SynQube GmbH geben eine strategische Partnerschaft in der Arzneimittelentwicklung mit Cannabinoiden und anderen psychotropen Substanzen bekannt
20. Juni 2024 01:00 ET
|
Avextra AG
Avextra, der führende europäische vertikal integrierte Hersteller und Entwickler von Medikamenten auf Cannabisbasis, erweitert nach Abschluss seiner Finanzierungsrunde im ersten Quartal 2024 seine...
Avextra AG and SynQube GmbH announce a Strategic Partnership in Drug Development with Cannabinoids and other Psychotropic Substances
20. Juni 2024 01:00 ET
|
Avextra AG
Avextra, the leading European vertically-integrated manufacturer and developer of cannabis-based medicines is expanding its pharmaceutical development capabilities. Behind SynQube GmbH are the two...
Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors
07. Februar 2024 07:00 ET
|
Avextra AG
Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors
German Pain Association (DGS) and Pharmaceutical Company Avextra Join Forces to Launch Their New Study OCEAN
23. Januar 2024 03:30 ET
|
Avextra AG
German Pain Association (DGS) and Pharmaceutical Company Avextra Join Forces to Launch Their New Study OCEAN
Avextra Unveils its Alliance for Evidence and Announces its Support of BELCANTO: A Clinical Trial for Oncology Patients
18. Oktober 2023 07:00 ET
|
Avextra AG
Avextra is launching its Alliance for Evidence-based Cannabis Medicine: a platform focused on collaborating with healthcare professionals and researchers to generate real-world patient data with the...
Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy
17. Mai 2023 07:00 ET
|
Avextra AG
Avextra has successfully exported EU-GMP standardised cannabis extracts manufactured at its German facility to its distribution partner in ItalyAvextra extracts are the first Made in Germany products...
Cannabis Suisse Corp. Has Announced a New Two-Year Distribution Agreement
21. Mai 2020 09:00 ET
|
Cannabis Suisse Corp.
Dietikon, Switzerland, May 21, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Suisse Corp. (CSUI), being a fully licensed Swiss cannabis cultivation and distribution company for recreational...